The first FDA-approved once-weekly basal insulin is entering the U.S. market. For adults with type 2 diabetes who need basal insulin, Awiqli could reduce injections from about 365 a year to 52. But cost, insurance coverage and safe use will determine who can actually benefit.
For some people with type 2 diabetes, insulin treatment means another injection every day.
A new option could change that routine.
The FDA’s 2026 novel drug approvals lists Awiqli, also known as insulin icodec-abae, as approved March 26, 2026, to improve blood-sugar control in adults with type 2 diabetes. The FDA’s Awiqli product record identifies it as a prescription injectable made by Novo Nordisk.
The significance is the schedule.
Awiqli is taken once a week on the same day, instead of daily basal insulin. Novo Nordisk says the treatment is designed to reduce basal-insulin injections from seven per week to one.
For someone who otherwise takes basal insulin every day, that could mean going from roughly 365 injections a year to 52.
But fewer injections do not automatically mean easier diabetes care.
For patients and families, the bigger questions are whether Awiqli is appropriate, whether insurance will cover it, what it will actually cost and how safely a weekly insulin should be used.
Why fewer injections could matter
Daily insulin can become a significant part of a person’s routine. Research has linked insulin nonadherence with factors including treatment burden, cost, discomfort and the demands of fitting injections into everyday life.
That makes a weekly option potentially meaningful.
The Awiqli clinical program compared once-weekly insulin icodec with daily basal insulin in adults with type 2 diabetes and found that the weekly treatment effectively lowered A1C. Novo Nordisk’s summary of the Phase 3 ONWARDS trials reports that the program included about 2,680 adults with type 2 diabetes.
There is also a legitimate Latino health connection.
Latino communities experience a substantial diabetes burden, while research has identified medication-adherence challenges among Latino patients. A weekly injection could remove one practical barrier for some people, although there is not yet evidence that Awiqli specifically improves adherence among Latino patients.
That distinction matters.
Parriva has been following the larger affordability and access problems facing California families in Latino Californians Face Growing Health Care Challenges as Insurance Coverage Becomes More Uncertain. For Awiqli, the same question applies: a treatment is only useful if patients can actually obtain it.
Awiqli does not replace every diabetes treatment
Awiqli is a basal insulin, meaning it provides background insulin throughout the week.
It does not necessarily replace mealtime, rapid-acting insulin for patients who need it. Some people will also continue taking other diabetes medications.
The FDA-approved prescribing information for Awiqli provides specific instructions for patients switching from daily basal insulin and warns that dosing should be determined by a health care professional.
So the simplest way to understand the change is:
Fewer basal-insulin injections, not fewer diabetes-care decisions.
What does Awiqli cost?
This is where the promise of convenience meets the reality of health-care costs.
Awiqli’s list price is $99 per package, according to current company and launch information. The amount a patient actually pays can be substantially different depending on insurance and eligibility for savings programs.
For eligible people with commercial insurance, Novo Nordisk’s Awiqli savings information says the monthly prescription cost can be as little as $35 and no more than $55, subject to program terms and eligibility.
That does not mean every insured patient will pay $35.
Before switching, patients should ask their insurance company or pharmacist:
- Is Awiqli on my formulary?
- Do I need prior authorization?
- What is my actual copay?
- Am I eligible for the manufacturer’s savings program?
What about Medicare?
Medicare patients may have an important cost advantage.
The federal insulin cost-sharing limit caps the out-of-pocket cost of covered insulin at $35 or less per month for eligible Medicare Part D beneficiaries. Novo Nordisk says eligible patients can receive Awiqli within that limit when the drug is covered by their plan.
But there is an important distinction:
The $35 cap does not mean every Medicare plan automatically covers Awiqli.
Patients should check their specific Medicare Part D or Medicare Advantage formulary before assuming the medication will be available.
What about Medi-Cal?
For Californians with Medi-Cal, patients should verify coverage rather than assume Awiqli is already universally covered.
Prescription medicines are administered through Medi-Cal Rx, and coverage can depend on the current formulary and authorization requirements.
That makes the state’s Medi-Cal Rx drug lookup an important resource for patients, pharmacists and providers checking current coverage.
The issue is particularly relevant as California continues to navigate changes to Medi-Cal access. Parriva has been tracking those changes, including California’s Medi-Cal renewal and coverage challenges and the broader uncertainty surrounding the state’s Medicaid program.
For Awiqli, the safest advice is simple: check current coverage before assuming the medication will be covered or affordable.
The safety issue patients should understand
Awiqli’s biggest advantage, its long duration, is also one reason patients need to follow dosing instructions carefully.
Insulin can cause hypoglycemia, or dangerously low blood sugar, and the FDA-approved label includes warnings about hypoglycemia and medication errors.
Because Awiqli is designed to remain active throughout the week, patients should not change the dose, take extra insulin or switch from another insulin without guidance from their health care provider.
The FDA’s prescribing information specifically provides instructions for transitioning from daily basal insulin and emphasizes monitoring blood glucose during the change.
That is an important message for anyone considering the new treatment:
Weekly does not mean risk-free.
Awiqli could represent a meaningful change for adults with type 2 diabetes who need basal insulin.
365 injections could become 52.
For someone who struggles with daily injections, that could make treatment easier to fit into everyday life.
But the real test will be access.
Patients need to know whether their insurance covers Awiqli, what they will actually pay, whether Medicare or Medi-Cal covers it, and whether the weekly treatment is appropriate for their individual medical needs.
For Latino and California communities, those questions may matter just as much as the medical innovation itself.
Awiqli makes the insulin schedule simpler.
Whether it makes diabetes care easier will depend on the patient, the treatment plan and whether the new option is actually affordable and accessible.
This article is for informational purposes and does not replace advice from a doctor, pharmacist or other qualified health professional. Patients should not change insulin doses or switch insulin products without guidance from their health care provider.
